Recent News

• 03.11.2025 - atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
• 03.11.2025 - atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
• 03.05.2025 - atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
• 03.05.2025 - atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 02.24.2025 - atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
• 02.24.2025 - atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
• 02.24.2025 - Mark Scott
• 02.20.2025 - atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Recent Filings

• 03.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.05.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.13.2025 - 424B5 Prospectus [Rule 424(b)(5)]